tradingkey.logo
tradingkey.logo
Search

Intellia Therapeutics Announces FDA Regenerative Medicine Advanced Therapy (RMAT) Designation Granted to Nexiguran Ziclumeran (nex-z)

ReutersMar 26, 2025 11:38 AM
facebooktwitterlinkedin

- Intellia Therapeutics Inc NTLA.O:

  • INTELLIA THERAPEUTICS ANNOUNCES FDA REGENERATIVE MEDICINE ADVANCED THERAPY (RMAT) DESIGNATION GRANTED TO NEXIGURAN ZICLUMERAN (NEX-Z) FOR THE TREATMENT OF TRANSTHYRETIN (ATTR) AMYLOIDOSIS WITH CARDIOMYOPATHY

Disclaimer: The information provided on this website is for educational and informational purposes only and should not be considered financial or investment advice.

Recommended Articles

Tradingkey
KeyAI